"The Global HIV Diagnostics Market was valued at USD 5.46 billion in 2025 and is projected to reach USD 12.78 billion by 2034, growing at a CAGR of 9.9%."
The HIV diagnostics market plays a crucial role in the global response to the HIV/AIDS epidemic by enabling early detection, monitoring, and treatment management. It encompasses a wide range of testing solutions, including antibody tests, nucleic acid tests (NAT), antigen/antibody combination tests, and point-of-care diagnostics. These tools are essential for reducing transmission rates and improving clinical outcomes through timely initiation of antiretroviral therapy (ART). The market is driven by growing public health initiatives, increasing awareness, and technological advancements in diagnostic platforms. Governments and international agencies have made widespread testing a priority, especially in high-prevalence regions across Africa, Asia, and Latin America. Private sector innovation is also expanding test accessibility through self-testing kits, digital platforms, and rapid diagnostic technologies, ensuring quicker diagnosis and decentralized care delivery.
Technological innovations in HIV diagnostics are centered around improving test sensitivity, reducing window periods, and enhancing affordability. High-income regions like North America and Western Europe lead in adoption of advanced laboratory-based diagnostics, while resource-limited settings are benefiting from affordable, portable, and easy-to-use point-of-care kits. Integration of HIV diagnostics with other infectious disease testing, such as hepatitis and tuberculosis, is emerging as a cost-effective approach in public health systems. Additionally, home-based and mobile testing services are gaining momentum, especially among key populations with limited access to traditional healthcare facilities. With increasing emphasis on early detection, viral load monitoring, and drug resistance profiling, the HIV diagnostics market continues to evolve as a cornerstone of global health infrastructure targeting disease elimination goals by 2030.
North America HIV Diagnostics Market:
The HIV diagnostics market in North America is mature and well-regulated, supported by comprehensive public health initiatives, insurance coverage, and advanced clinical infrastructure. High testing volumes are sustained by mandatory screenings in healthcare settings, blood banks, and for pregnant women. The region shows increasing adoption of fourth-generation and nucleic acid-based tests, which offer improved detection during early infection stages. Home testing kits and digital platforms are gaining popularity, enhancing privacy and accessibility. Strategic collaborations between diagnostics companies and healthcare providers are fostering innovation in rapid diagnostics and integrated digital health solutions, presenting lucrative expansion opportunities.
Asia Pacific HIV Diagnostics Market:
The Asia Pacific market is emerging as a high-growth region, fueled by rising HIV incidence, urbanization, and expanded access to diagnostics through government-funded programs and international support. Countries like India, Thailand, and Vietnam are focusing on scaling up rapid testing initiatives, particularly in underserved and high-risk populations. Mobile diagnostic units, self-test kits, and awareness campaigns are enhancing screening outreach in rural and peri-urban regions. The growing presence of regional diagnostic manufacturers and the shift toward decentralized testing models create favorable conditions for market expansion. Opportunities lie in affordable, user-friendly, and scalable testing technologies tailored to the region’s diverse healthcare environments.
Europe HIV Diagnostics Market:
Europe’s HIV diagnostics market benefits from strong public health frameworks, high awareness levels, and robust disease surveillance systems. Western European countries lead in the adoption of advanced laboratory diagnostics, while Eastern Europe is witnessing increased use of point-of-care and mobile testing due to rising HIV rates. Integrated diagnostic solutions that combine HIV, STI, and hepatitis testing are gaining traction, particularly in community health centers and outreach clinics. Policy-driven initiatives supporting routine testing and destigmatization campaigns are further increasing uptake. Companies in the region are capitalizing on regulatory support to launch innovative testing platforms and expand service accessibility across both urban and remote areas.
Key Insights
- The HIV diagnostics market is expanding due to heightened awareness, government initiatives, and global health organization mandates promoting early diagnosis and treatment to curb HIV transmission and reduce AIDS-related mortality. Regular screening and test integration into public health systems are improving access across diverse population groups.
- Fourth-generation combination tests that detect both HIV antibodies and p24 antigen are increasingly replacing older technologies due to their shorter window periods and higher accuracy. These tests are particularly useful for early diagnosis, allowing quicker initiation of antiretroviral therapy.
- Point-of-care (POC) diagnostics are playing a critical role in remote and resource-limited regions. Their rapid turnaround time, minimal training requirement, and portability are key drivers, especially in sub-Saharan Africa and parts of Asia where access to centralized laboratories is limited.
- Self-testing kits are gaining popularity among high-risk and underserved populations. These at-home diagnostic tools reduce stigma, promote privacy, and support broader screening coverage, particularly among individuals hesitant to seek facility-based testing.
- The North American market is driven by robust healthcare infrastructure, high rates of routine screening, and integration of HIV diagnostics in sexual health services. Public-private collaborations have facilitated access to innovative technologies and ensured a steady supply of testing products.
- Europe is witnessing a shift toward integrated testing approaches that combine HIV screening with tests for other sexually transmitted infections (STIs). National healthcare systems are promoting multi-disease diagnostic platforms to improve testing efficiency and reduce costs.
- Asia Pacific is experiencing rapid growth in HIV diagnostics adoption due to increasing government-led prevention campaigns, international funding, and partnerships with diagnostic firms. Urban centers are seeing a surge in private testing labs offering quick and anonymous services.
- Technological advancements such as lab-on-a-chip diagnostics, digital readers, and smartphone-based testing are enhancing the precision and traceability of HIV diagnostics. These tools offer opportunities for remote data collection and integration into patient health records.
- Global health initiatives, such as UNAIDS’ 95-95-95 targets, are driving investment in scaling up testing infrastructure. These frameworks aim to diagnose 95% of all HIV-positive individuals, offer treatment to 95%, and achieve viral suppression in 95% of those treated.
- Leading diagnostic companies are focusing on strategic partnerships with non-governmental organizations and local governments to expand distribution channels. These collaborations aim to address supply chain challenges, improve affordability, and localize manufacturing in high-burden countries.
Market Scope
| Parameter | Detail |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2026-2034 |
| Market Size-Units | USD billion |
| Market Splits Covered | By Product Type , By Application , By End User , By Technology , By Distribution Channel |
| Countries Covered | North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) |
| Analysis Covered | Latest Trends, Driving Factors, Challenges, Supply-Chain Analysis, Competitive Landscape, Company Strategies |
| Customization | 10 % free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed |
| Post-Sale Support | 4 analyst hours, available up to 4 weeks |
| Delivery Format | The Latest Updated PDF and Excel Datafile |
HIV Diagnostics Market Segmentation
By Product Type
- Test Kits
- Reagents
By Application
- Clinical
- Home Care
By End User
- Hospitals
- Diagnostic Laboratories
By Technology
- PCR
- Rapid Testing
By Distribution Channel
- Online
- Offline
By Geography
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Key Companies Covered
Abbott Laboratories, Siemens Healthineers AG, F. Hoffmann‑La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific Inc., bioMérieux SA, Grifols S.A., Becton, Dickinson and Company (BD), Hologic Inc., QIAGEN NV, Trinity Biotech, OraSure Technologies, Chembio Diagnostics (BioSynex), Bio‑Rad Laboratories, Alere Inc., Sysmex Corp., Mylan N.V., Getein Biotech Inc., Guangzhou Wondfo Biotech, Beckman Coulter (Danaher), jew York‑based bioSynex.Recent Developments
- July 2025: ViiV Healthcare expanded voluntary licensing of its long-acting injectable treatments to the Medicines Patent Pool, aiming to increase access to HIV therapy in low- and middle-income countries.
- June 2025: Gilead Sciences received FDA approval for lenacapavir (Yeztugo), the first twice-yearly injectable HIV prevention option, representing a major advancement in PrEP adherence and convenience.
- June 2025: The World Health Organization acknowledged the approval of lenacapavir as a milestone in global HIV prevention, supporting broader international rollout and access strategies.
- June 2025: Chembio Diagnostic Systems received Breakthrough Device designation from the FDA for its SURE CHECK® HIV Self-Test, accelerating its path toward U.S. commercialization.
- May 2025: Gilead announced plans to provide lenacapavir for HIV prevention through global initiatives like PEPFAR and the Global Fund, targeting widespread availability in low-income regions.
- March 2025: ViiV Healthcare reported strong real-world data for its injectable PrEP drug, cabotegravir (Apretude), with zero new HIV infections recorded in U.S. and Brazil-based prevention studies.
What You Receive
• Global HIV Diagnostics market size and growth projections (CAGR), 2024- 2034• Impact of recent changes in geopolitical, economic, and trade policies on the demand and supply chain of HIV Diagnostics.
• HIV Diagnostics market size, share, and outlook across 5 regions and 27 countries, 2025- 2034.
• HIV Diagnostics market size, CAGR, and Market Share of key products, applications, and end-user verticals, 2025- 2034.
• Short and long-term HIV Diagnostics market trends, drivers, restraints, and opportunities.
• Porter’s Five Forces analysis, Technological developments in the HIV Diagnostics market, HIV Diagnostics supply chain analysis.
• HIV Diagnostics trade analysis, HIV Diagnostics market price analysis, HIV Diagnostics Value Chain Analysis.
• Profiles of 5 leading companies in the industry- overview, key strategies, financials, and products.
• Latest HIV Diagnostics market news and developments.
The HIV Diagnostics Market international scenario is well established in the report with separate chapters on North America HIV Diagnostics Market, Europe HIV Diagnostics Market, Asia-Pacific HIV Diagnostics Market, Middle East and Africa HIV Diagnostics Market, and South and Central America HIV Diagnostics Markets. These sections further fragment the regional HIV Diagnostics market by type, application, end-user, and country.
1.1 List of Tables
1.2 List of Figures
2. HIV Diagnostics Market Latest Trends, Drivers and Challenges, 2024- 2034
2.1 HIV Diagnostics Market Overview
2.2 Market Strategies of Leading HIV Diagnostics Companies
2.3 HIV Diagnostics Market Insights, 2024- 2034
2.3.1 Leading HIV Diagnostics Types, 2024- 2034
2.3.2 Leading HIV Diagnostics End-User industries, 2024- 2034
2.3.3 Fast-Growing countries for HIV Diagnostics sales, 2024- 2034
2.4 HIV Diagnostics Market Drivers and Restraints
2.4.1 HIV Diagnostics Demand Drivers to 2034
2.4.2 HIV Diagnostics Challenges to 2034
2.5 HIV Diagnostics Market- Five Forces Analysis
2.5.1 HIV Diagnostics Industry Attractiveness Index, 2024
2.5.2 Threat of New Entrants
2.5.3 Bargaining Power of Suppliers
2.5.4 Bargaining Power of Buyers
2.5.5 Intensity of Competitive Rivalry
2.5.6 Threat of Substitutes
3. Global HIV Diagnostics Market Value, Market Share, and Forecast to 2034
3.1 Global HIV Diagnostics Market Overview, 2024
3.2 Global HIV Diagnostics Market Revenue and Forecast, 2024- 2034 (US$ billion)
3.3 Global HIV Diagnostics Market Size and Share Outlook By Product, 2024- 2034
3.4 Global HIV Diagnostics Market Size and Share Outlook By Application, 2024- 2034
3.5 Global HIV Diagnostics Market Size and Share Outlook By End User, 2024- 2034
3.6 Global HIV Diagnostics Market Size and Share Outlook By Technology, 2024- 2034
3.7 Global HIV Diagnostics Market Size and Share Outlook by Region, 2024- 2034
4. Asia Pacific HIV Diagnostics Market Value, Market Share and Forecast to 2034
4.1 Asia Pacific HIV Diagnostics Market Overview, 2024
4.2 Asia Pacific HIV Diagnostics Market Revenue and Forecast, 2024- 2034 (US$ billion)
4.3 Asia Pacific HIV Diagnostics Market Size and Share Outlook By Product, 2024- 2034
4.4 Asia Pacific HIV Diagnostics Market Size and Share Outlook By Application, 2024- 2034
4.5 Asia Pacific HIV Diagnostics Market Size and Share Outlook By End User, 2024- 2034
4.6 Asia Pacific HIV Diagnostics Market Size and Share Outlook By Technology, 2024- 2034
4.7 Asia Pacific HIV Diagnostics Market Size and Share Outlook by Country, 2024- 2034
5. Europe HIV Diagnostics Market Value, Market Share, and Forecast to 2034
5.1 Europe HIV Diagnostics Market Overview, 2024
5.2 Europe HIV Diagnostics Market Revenue and Forecast, 2024- 2034 (US$ billion)
5.3 Europe HIV Diagnostics Market Size and Share Outlook By Product, 2024- 2034
5.4 Europe HIV Diagnostics Market Size and Share Outlook By Application, 2024- 2034
5.5 Europe HIV Diagnostics Market Size and Share Outlook By End User, 2024- 2034
5.6 Europe HIV Diagnostics Market Size and Share Outlook By Technology, 2024- 2034
5.7 Europe HIV Diagnostics Market Size and Share Outlook by Country, 2024- 2034
6. North America HIV Diagnostics Market Value, Market Share and Forecast to 2034
6.1 North America HIV Diagnostics Market Overview, 2024
6.2 North America HIV Diagnostics Market Revenue and Forecast, 2024- 2034 (US$ billion)
6.3 North America HIV Diagnostics Market Size and Share Outlook By Product, 2024- 2034
6.4 North America HIV Diagnostics Market Size and Share Outlook By Application, 2024- 2034
6.5 North America HIV Diagnostics Market Size and Share Outlook By End User, 2024- 2034
6.6 North America HIV Diagnostics Market Size and Share Outlook By Technology, 2024- 2034
6.7 North America HIV Diagnostics Market Size and Share Outlook by Country, 2024- 2034
7. South and Central America HIV Diagnostics Market Value, Market Share and Forecast to 2034
7.1 South and Central America HIV Diagnostics Market Overview, 2024
7.2 South and Central America HIV Diagnostics Market Revenue and Forecast, 2024- 2034 (US$ billion)
7.3 South and Central America HIV Diagnostics Market Size and Share Outlook By Product, 2024- 2034
7.4 South and Central America HIV Diagnostics Market Size and Share Outlook By Application, 2024- 2034
7.5 South and Central America HIV Diagnostics Market Size and Share Outlook By End User, 2024- 2034
7.6 South and Central America HIV Diagnostics Market Size and Share Outlook By Technology, 2024- 2034
7.7 South and Central America HIV Diagnostics Market Size and Share Outlook by Country, 2024- 2034
8. Middle East Africa HIV Diagnostics Market Value, Market Share and Forecast to 2034
8.1 Middle East Africa HIV Diagnostics Market Overview, 2024
8.2 Middle East and Africa HIV Diagnostics Market Revenue and Forecast, 2024- 2034 (US$ billion)
8.3 Middle East Africa HIV Diagnostics Market Size and Share Outlook By Product, 2024- 2034
8.4 Middle East Africa HIV Diagnostics Market Size and Share Outlook By Application, 2024- 2034
8.5 Middle East Africa HIV Diagnostics Market Size and Share Outlook By End User, 2024- 2034
8.6 Middle East Africa HIV Diagnostics Market Size and Share Outlook By Technology, 2024- 2034
8.7 Middle East Africa HIV Diagnostics Market Size and Share Outlook by Country, 2024- 2034
9. HIV Diagnostics Market Structure
9.1 Key Players
9.2 HIV Diagnostics Companies - Key Strategies and Financial Analysis
9.2.1 Snapshot
9.2.3 Business Description
9.2.4 Products and Services
9.2.5 Financial Analysis
10. HIV Diagnostics Industry Recent Developments
11 Appendix
11.1 Publisher Expertise
11.2 Research Methodology
11.3 Annual Subscription Plans
11.4 Contact Information
Get Free Sample
At OG Analysis, we understand the importance of informed decision-making in today's dynamic business landscape. To help you experience the depth and quality of our market research reports, we offer complimentary samples tailored to your specific needs.
Start Now! Please fill the form below for your free sample.
Why Request a Free Sample?
Evaluate Our Expertise: Our reports are crafted by industry experts and seasoned analysts. Requesting a sample allows you to assess the depth of research and the caliber of insights we provide.
Tailored to Your Needs: Let us know your industry, market segment, or specific topic of interest. Our free samples are customized to ensure relevance to your business objectives.
Witness Actionable Insights: See firsthand how our reports go beyond data, offering actionable insights and strategic recommendations that can drive your business forward.
Embark on your journey towards strategic decision-making by requesting a free sample from OG Analysis. Experience the caliber of insights that can transform the way you approach your business challenges.
FAQ's
The Global HIV Diagnostics Market is estimated to generate USD 5.46 billion in revenue in 2025.
The Global HIV Diagnostics Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.9% during the forecast period from 2025 to 2034.
The HIV Diagnostics Market is estimated to reach USD 12.78 billion by 2034.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!
